PDCD1 and neoplasm: In recent times, more than four checkpoint antibody inhibitors targeting PD-1, PDL-1, and CTLA-4 have been commercialized, and these checkpoint blockers are rapidly becoming a promising cancer treatment with significant anti-tumor responses and limited side effects [23].